COSMOS Pharmaceutical Corporation (CSMYF)
USD 46.06
(-0.22%)
USD 46.06
(-0.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -18.23 Billion JPY | 34.22% |
| 2023 | -27.72 Billion JPY | 0.79% |
| 2022 | -27.94 Billion JPY | 37.42% |
| 2021 | -44.66 Billion JPY | -11.66% |
| 2020 | -40 Billion JPY | -677.17% |
| 2019 | -5.14 Billion JPY | -15.22% |
| 2018 | -4.46 Billion JPY | 24.97% |
| 2017 | -5.95 Billion JPY | -869.71% |
| 2016 | -614 Million JPY | 59.23% |
| 2015 | -1.5 Billion JPY | 89.73% |
| 2014 | -14.66 Billion JPY | -19.76% |
| 2013 | -12.24 Billion JPY | 11.66% |
| 2012 | -13.86 Billion JPY | -21.51% |
| 2011 | -11.4 Billion JPY | -83.16% |
| 2010 | -6.22 Billion JPY | -50.18% |
| 2009 | -4.14 Billion JPY | -153.02% |
| 2008 | -1.63 Billion JPY | -491.17% |
| 2007 | 419 Million JPY | 109.19% |
| 2006 | -4.55 Billion JPY | -1847.44% |
| 2005 | -234 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -7.74 Billion JPY | 57.68% |
| 2024 Q4 | -18.23 Billion JPY | -135.42% |
| 2024 FY | -18.23 Billion JPY | 34.22% |
| 2024 Q2 | -18.3 Billion JPY | 45.9% |
| 2024 Q1 | -33.84 Billion JPY | -22.05% |
| 2023 Q3 | -18.02 Billion JPY | 30.75% |
| 2023 FY | -27.72 Billion JPY | 0.79% |
| 2023 Q4 | -27.72 Billion JPY | -53.84% |
| 2023 Q2 | -26.02 Billion JPY | 27.15% |
| 2023 Q1 | -35.72 Billion JPY | -27.83% |
| 2022 Q4 | -27.94 Billion JPY | -4.23% |
| 2022 Q3 | -26.81 Billion JPY | 26.89% |
| 2022 FY | -27.94 Billion JPY | 37.42% |
| 2022 Q1 | -45.13 Billion JPY | -1.05% |
| 2022 Q2 | -36.67 Billion JPY | 18.74% |
| 2021 Q4 | -44.66 Billion JPY | -9.73% |
| 2021 Q1 | -39.33 Billion JPY | 1.66% |
| 2021 Q3 | -40.7 Billion JPY | -22.01% |
| 2021 Q2 | -33.36 Billion JPY | 15.19% |
| 2021 FY | -44.66 Billion JPY | -11.66% |
| 2020 Q4 | -40 Billion JPY | -183.41% |
| 2020 FY | -40 Billion JPY | -677.17% |
| 2020 Q1 | -10.14 Billion JPY | -97.18% |
| 2020 Q2 | -9.37 Billion JPY | 7.6% |
| 2020 Q3 | -14.11 Billion JPY | -50.5% |
| 2019 Q1 | -9.87 Billion JPY | -121.0% |
| 2019 Q4 | -5.14 Billion JPY | -14397.22% |
| 2019 FY | -5.14 Billion JPY | -15.22% |
| 2019 Q2 | -3.55 Billion JPY | 64.01% |
| 2019 Q3 | 36 Million JPY | 101.01% |
| 2018 FY | -4.46 Billion JPY | 24.97% |
| 2018 Q2 | -7.17 Billion JPY | 47.41% |
| 2018 Q1 | -13.63 Billion JPY | -129.06% |
| 2018 Q4 | -4.46 Billion JPY | -101.85% |
| 2018 Q3 | -2.21 Billion JPY | 69.14% |
| 2017 Q4 | -5.95 Billion JPY | -1749.31% |
| 2017 FY | -5.95 Billion JPY | -869.71% |
| 2017 Q3 | 361 Million JPY | 108.77% |
| 2017 Q2 | -4.11 Billion JPY | 36.39% |
| 2017 Q1 | -6.47 Billion JPY | -954.07% |
| 2016 Q1 | -6.28 Billion JPY | -317.26% |
| 2016 FY | -614 Million JPY | 59.23% |
| 2016 Q4 | -614 Million JPY | -112.81% |
| 2016 Q3 | 4.79 Billion JPY | 1975.76% |
| 2016 Q2 | 231 Million JPY | 103.68% |
| 2015 Q2 | -10.7 Billion JPY | 45.71% |
| 2015 Q3 | -7.02 Billion JPY | 34.33% |
| 2015 Q4 | -1.5 Billion JPY | 78.57% |
| 2015 FY | -1.5 Billion JPY | 89.73% |
| 2015 Q1 | -19.71 Billion JPY | -34.41% |
| 2014 Q2 | -9.56 Billion JPY | 23.39% |
| 2014 Q3 | -9.32 Billion JPY | 2.47% |
| 2014 FY | -14.66 Billion JPY | -19.76% |
| 2014 Q1 | -12.48 Billion JPY | -1.96% |
| 2014 Q4 | -14.66 Billion JPY | -57.2% |
| 2013 Q4 | -12.24 Billion JPY | -64.85% |
| 2013 Q2 | -15.08 Billion JPY | 16.66% |
| 2013 FY | -12.24 Billion JPY | 11.66% |
| 2013 Q1 | -18.09 Billion JPY | -30.55% |
| 2013 Q3 | -7.42 Billion JPY | 50.74% |
| 2012 FY | -13.86 Billion JPY | -21.51% |
| 2012 Q3 | -9.62 Billion JPY | 23.7% |
| 2012 Q2 | -12.61 Billion JPY | 11.46% |
| 2012 Q4 | -13.86 Billion JPY | -44.04% |
| 2012 Q1 | -14.24 Billion JPY | -24.87% |
| 2011 Q2 | -8.82 Billion JPY | 7.11% |
| 2011 FY | -11.4 Billion JPY | -83.16% |
| 2011 Q4 | -11.4 Billion JPY | -71.79% |
| 2011 Q3 | -6.64 Billion JPY | 24.73% |
| 2011 Q1 | -9.49 Billion JPY | -52.49% |
| 2010 Q3 | -1.29 Billion JPY | 0.0% |
| 2010 FY | -6.22 Billion JPY | -50.18% |
| 2010 Q4 | -6.22 Billion JPY | -381.67% |
| 2009 Q3 | 46 Million JPY | 102.52% |
| 2009 FY | -4.14 Billion JPY | -153.02% |
| 2009 Q2 | -1.82 Billion JPY | 0.0% |
| 2009 Q4 | -4.14 Billion JPY | -9115.22% |
| 2008 FY | -1.63 Billion JPY | -491.17% |
| 2007 FY | 419 Million JPY | 109.19% |
| 2006 FY | -4.55 Billion JPY | -1847.44% |
| 2005 FY | -234 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | 415.78 Thousand USD | 4386469.977% |
| Allstar Health Brands, Inc. | 2.21 Million USD | 825324.224% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | -111.13 Million USD | -16311.385% |
| Café Serendipity Holdings, Inc. | 409.94 Thousand USD | 4449022.043% |
| Decision Diagnostics Corp. | - USD | Infinity% |
| Health Advance Inc. | 271.74 Thousand USD | 6711662.523% |
| HealthWarehouse.com, Inc. | 2.17 Million USD | 839803.162% |
| LIGAND PHARMACEUTICAL INC | -16.78 Million USD | -108530.651% |
| MedGen, Inc. | 24.36 USD | 74868637210.016% |
| Omni Health, Inc. | 1.46 Million USD | 1247604.205% |
| Oxford Investments Holdings Inc. | 172.66 Thousand USD | 10562566.699% |
| Pineapple, Inc. | 8.1 Million USD | 224997.503% |
| ScripsAmerica, Inc. | 748.59 Thousand USD | 2436407.094% |